Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.36 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.36 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.36 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546692 | 0.91 | MCHR1 (0.38) | KAT2BBAZ2B | |
| SCHEMBL673268 | 0.78 | KAT2B (0.49) | KAT2BBAZ2BSYKTBK1IKBKE | |
| SCHEMBL1667102 | 0.78 | TBK1 (0.49) | KAT2BBAZ2BTBK1IKBKEPDE9A | |
| Ammonia Solution, Strong SCHEMBL28707534 | 0.77 | KAT2B (0.51) | KAT2BBAZ2BTBK1IKBKEPDE9A | |
| SCHEMBL7712474 | 0.76 | KDM4C (0.35) | — | |
| SCHEMBL3846189 | 0.73 | ALDH1A1 (0.41) | — | |
| SCHEMBL12180578 | 0.73 | KAT2B (0.56) | KAT2BBAZ2BSYKPDE4D | |
| SCHEMBL3798831 | 0.73 | KAT2B (0.53) | KAT2BBAZ2BSYKCACNB4CACNA1A | |
| SCHEMBL852452 | 0.72 | GRM5 (0.49) | — | |
| SCHEMBL29636414 | 0.72 | GRM5 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110160301-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | TKT, HAAO, TTPA | KAT2B 1934/4885BAZ2B 4738/4885SYK 2878/4885 |
| US-20110160301-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | PROC, VKORC1L1, VKORC1 | KAT2B 3362/4885BAZ2B 3399/4885SYK 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.